182748-72-7

Basic information

• Product Name: Boc-D-aspartinol 4-Benzyl Ester
• Synonyms: Boc-D-aspartinol 4-Benzyl Ester;benzyl(R)-3-((tert-butoxycarbonyl)amino)-4-hydroxybutanoate;EOS-62150
• CAS NO: 182748-72-7
• Molecular Formula: C₁₆H₂₃NO₅
• Molecular Weight: 309.35752
• Mol File: 182748-72-7.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Boc-D-aspartinol 4-Benzyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-D-aspartinol 4-Benzyl Ester(182748-72-7)
• EPA Substance Registry System: Boc-D-aspartinol 4-Benzyl Ester(182748-72-7)

Safety Data

• Hazardous Substances Data: 182748-72-7(Hazardous Substances Data)

Usage

General Description

Boc-D-aspartinol 4-Benzyl Ester is a chemical compound used in organic synthesis and drug development. It is a derivative of aspartic acid, which is an important amino acid in the human body. Boc-D-aspartinol 4-Benzyl Ester is commonly used as a building block in the synthesis of peptide and protein-based drugs. Its structure and properties make it a valuable component in the creation of new pharmaceuticals, particularly in the treatment of neurological and psychiatric disorders. Additionally, its benzyl ester group provides stability and protection to the aspartic acid moiety, making it a versatile and widely used chemical in medicinal chemistry and drug discovery.

Upstream product

• 51186-58-4 4-benzyl Boc-D-aspartate 

Downstream Products

• 210963-56-7 benzyl (3R)-tert-butoxycarbonylamino-4-(5-cyano-2-iodophenoxy)butyric acid 
• 1135149-01-7 benzyl (R)-4-(allyloxy)-3-(tert-butoxycarbonylamino)-butanoate 
• 137105-97-6 (R)-4-(tert-butyloxycarbonylamino)-γ-butyrolactone 
• 1062238-49-6 methyl (3R)-3-{[(tert-butoxy)carbonyl]amino}-4-hydroxybutanoate 
• 1418006-26-4 (3R)-benzyl 3-amino-4-iodobutanoate hydrochloride 
• 1403953-52-5 (3R)-benzyl 3-(diphenylmethylideneamino)-4-iodobutanoate 
• 1403953-55-8 (1S,2S)-benzyl 2-(diphenylmethylideneamino)cyclopropanecarboxylate 
• 1059704-65-2 (R)-4-(benzyloxy)-N,N,N-trimethyl-4-oxo-2-(4-(trifluoromethyl)phenylsulfonamido)butan-1-aminium methanesulfonate 
• 1059704-48-1 (R)-4-(benzyloxy)-2-(tert-butoxycarbonylamino)-N,N,N-trimethyl-4-oxobutan-1-aminium methanesulfonate 
• 1059704-51-6 (R)-2-amino-4-(benzyloxy)-N,N,N-trimethyl-4-oxobutan-1-aminium methanesulfonate 
• 1059704-52-7 (R)-benzyl 3-(tert-butoxycarbonylamino)-4-(dimethylamino)butanoate 
• 1059704-46-9 benzyl (R)-3-((tert-butoxycarbonyl)amino)-4-((methylsulfonyl)oxy)butanoate 
• 252263-63-1 benzyl (3R)-3-t-butoxycarbonylamino-4-(5-cyano-2-benzyloxyphenoxy)butanoate 
• 556069-27-3 3-[2-(9H-fluoren-9-ylmethoxycarbonylamino)-acetylamino]-4-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-butyric acid benzyl ester 

Relevant articles and documents

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

B-cell lymphoma extra large (BCL-XL) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as ABT263, as safe and effective anticancer agents. To reduce

IMPROVED APELIN RECEPTOR (APJ) AGONISTS AND USES THEREOF

This disclosure is directed to agonists of the apelin receptor (APJ) and uses of such agonists.

HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS

The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel he